{"gene":"PDCD1LG2","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2001,"finding":"PD-L2 was identified as a second ligand for PD-1 that inhibits T cell activation: engagement of PD-1 by PD-L2 dramatically inhibits TCR-mediated proliferation and cytokine production by CD4+ T cells, leads to cell cycle arrest in G0/G1, and ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2.","method":"Cell-based binding assays, T cell proliferation and cytokine assays, Western blotting for SHP-2 phosphorylation","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — original identification paper with multiple orthogonal functional assays; widely replicated across many subsequent studies","pmids":["11224527"],"is_preprint":false},{"year":2003,"finding":"PD-L2 expression depends on IL-4Rα and STAT6 signaling, whereas PD-L1 expression depends on TLR4 and STAT1, demonstrating that PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 signals on macrophages; PD-L2 is induced by IL-4 (alternative activation) but not by LPS/IFN-γ (classical activation).","method":"Macrophage stimulation assays, STAT6-/- and STAT1-/- knockout cells, flow cytometry for surface expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal knockout validation with defined signaling pathway, replicated in multiple macrophage populations","pmids":["12697896"],"is_preprint":false},{"year":2003,"finding":"PD-L2 (B7-DC) can promote CD8 T cell-mediated tumor rejection via a PD-1-independent mechanism: B7-DC binds to PD-1-/- cells and enhances T cell killing, indicating a second receptor/pathway for B7-DC costimulation.","method":"Tumor rejection assays in PD-1-/- mice, T cell cytotoxicity assays, binding studies on PD-1-deficient cells","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo tumor rejection and in vitro binding with PD-1 KO cells, single lab","pmids":["12810690"],"is_preprint":false},{"year":2003,"finding":"PD-L2 transcription is regulated through NF-κB (p50/p65): PD-L2 expression was dramatically reduced in NF-κB p50-/-p65+/- dendritic cells, whereas PD-L1 was not similarly affected, demonstrating distinct transcriptional regulation of the two ligands.","method":"Genetic knockout (NF-κB p50-/-p65+/- mice), dendritic cell expression assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with transcription factor validation, single lab, single method","pmids":["14515254"],"is_preprint":false},{"year":2005,"finding":"PD-L2 inhibits human T cell proliferation, IL-2 and IFN-γ production via PD-1; this inhibition involves suppression of PI3K/AKT and ERK/MAPK pathways (PD-L2 inhibits anti-CD3-induced AKT phosphorylation within minutes and ERK phosphorylation after hours), and is accompanied by increased SHP-2 phosphatase activity associated with PD-1.","method":"Human T cell activation assays, phospho-AKT and phospho-ERK Western blotting, SHP-2 phosphatase activity assays, co-immunoprecipitation of SHP-2 with PD-1","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical assays (kinase/phosphatase activity, co-IP, Western blot), single lab","pmids":["16278812"],"is_preprint":false},{"year":2006,"finding":"PDL2 negatively regulates T cell activation and tolerance via PD-1: antigen-presenting cells from PDL2-/- mice were more potent in activating T cells in a PD-1-dependent manner; PDL2-/- mice showed increased CD4+ and CD8+ T cell activation in vivo and abrogated oral tolerance.","method":"PDL2 knockout mouse generation, in vitro T cell activation assays with APCs, in vivo immunization and tolerance induction, PD-1-dependent rescue experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with both in vitro and in vivo phenotypic readouts, PD-1-dependence confirmed","pmids":["16864790"],"is_preprint":false},{"year":2006,"finding":"PD-1/PD-L1, but not PD-1/PD-L2, interactions are crucial for attenuating T cell responses in experimental autoimmune encephalomyelitis (EAE): PD-L2-/- mice did not develop more severe EAE, unlike PD-1-/- and PD-L1-/- mice which showed elevated IFN-γ, TNF, IL-6, and IL-17.","method":"PD-L2-/- mouse immunization for EAE induction, cytokine measurement by ELISA, disease severity scoring","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined disease phenotype and cytokine readouts, single lab; notable as a negative finding distinguishing PD-L2 from PD-L1 in this context","pmids":["17182110"],"is_preprint":false},{"year":2009,"finding":"PD-L2 on lung dendritic cells plays an inhibitory role on iNKT cell activation: PD-L2-/- mice showed greater airway hyperreactivity and higher IL-4 production by iNKT cells; blocking PD-L2 in vitro enhanced IL-4 production. PD-L2 expression on lung DCs is upregulated by allergen and IL-4. In contrast, PD-L1 deficiency reduced AHR, demonstrating opposing roles for the two ligands.","method":"PD-L2-/- and PD-L1-/- mouse models, allergen and α-GalCer challenge, iNKT cell transfer experiments, in vitro PD-L2 blockade, cytokine measurement","journal":"Mucosal immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal KO models (PD-L1-/- vs PD-L2-/-), cell transfer experiments, in vitro blockade, multiple orthogonal readouts","pmids":["19741598"],"is_preprint":false},{"year":2010,"finding":"PD-L1 and PD-L2 bind PD-1 with comparable overall affinities but with distinct kinetic mechanisms: PD-L1 shows a delayed interaction consistent with conformational transition, while PD-L2 does not; PD-L1 and PD-L2 compete for the same PD-1 binding site.","method":"Surface plasmon resonance (SPR), cell surface binding assays, competition experiments with blocking mAbs","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — SPR-based real-time binding kinetics with multiple validation methods (cell binding, competition), single lab","pmids":["20587542"],"is_preprint":false},{"year":2011,"finding":"PD-L2 is expressed on activated human CD4+ and CD8+ T cells (not only on APCs), and PD-L2 engagement at the surface of T cells downregulates cytokine production and cell proliferation, indicating a bidirectional regulatory role.","method":"Flow cytometry for PD-L2 surface expression on T cell subsets, functional assays with PD-L2 engagement on T cells","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct expression analysis and functional engagement on primary human T cells, single lab, two methods","pmids":["21752471"],"is_preprint":false},{"year":2012,"finding":"PD-L2 promotes airway hyperresponsiveness via a PD-1-independent mechanism by inhibiting dendritic cell IL-12 production: PD-L2 blockade reduced allergen-induced AHR and enhanced serum IL-12, while PD-1 blockade had no effect; in vitro, PD-L2-Fc stimulation of DCs reduced IL-12 p70 production.","method":"PD-L2 blockade in murine asthma model, PD-1 blockade comparison, in vitro DC stimulation with PD-L2-Fc, IL-12 ELISA","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo blockade plus in vitro mechanistic assay, PD-1 independence confirmed by parallel blockade experiment, single lab","pmids":["23149662"],"is_preprint":false},{"year":2017,"finding":"PD-L2 expression is primarily regulated by both IRF1 and STAT3 in response to interferons: IRF1 and STAT3 bind to the PD-L2 promoter; PD-L2 responds equally to interferon-beta and interferon-gamma, unlike PD-L1 which is primarily regulated by the IFN-γ-JAK1/JAK2-STAT1/STAT2/STAT3-IRF1 axis.","method":"siRNA knockdown of signaling components (JAK1, JAK2, STAT1, STAT2, STAT3, IRF1), chromatin immunoprecipitation (ChIP) for IRF1 and STAT3 at PD-L2 promoter, interferon stimulation of melanoma cells","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP demonstrating direct promoter binding combined with genetic knockdown, multiple transcription factors validated, replicated in patient biopsies","pmids":["28494868"],"is_preprint":false},{"year":2017,"finding":"PD-L2 (B7-DC) binds RGMb (repulsive guidance molecule b) as a second receptor distinct from PD-1; a PD-1-binding-deficient PD-L2 mutant (K113S) retains binding to RGMb with similar affinity to wild-type and can costimulate CD4+ T cell Th1 responses via RGMb, promoting Th1 polarization and suppressing Th2-mediated asthma.","method":"PD-L2 K113S mutant protein binding assays, recombinant protein co-stimulation assays, RGMb expression analysis on immune cells, murine asthma model","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding assays with defined mutant plus functional T cell assays and in vivo disease model, single lab","pmids":["28479601"],"is_preprint":false},{"year":2019,"finding":"PD-L2 has a higher affinity for PD-1 (approximately 3-fold) than PD-L1, attributable to two structural features that evolved in placental mammals: a C-D β-strand 'latch' that enhances affinity and a W110 'elbow' that acts to reduce engagement duration; these two opposing features combine to give the net 3-fold affinity advantage of PD-L2.","method":"Surface plasmon resonance (SPR) with recombinant proteins, mutational analysis of W110 and C-D region, phylogenetic analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — SPR-based real-time binding kinetics with systematic mutagenesis of key structural determinants, single lab with multiple orthogonal mutations tested","pmids":["31882544"],"is_preprint":false},{"year":2019,"finding":"Binding of PD-L2 to human PD-1 induces formation of a prominent pocket in the CC' and FG loop regions of PD-1 via substantial conformational changes; a triple-mutant high-affinity PD-1 variant (two orders of magnitude higher affinity for PD-L2) enabled crystallization of the human PD-1/PD-L2 complex, revealing the structural basis of the interaction.","method":"Deep mutational scanning, yeast surface display selection, X-ray crystallography of human PD-1/PD-L2 complex at 2.0 Å and apo PD-1 at 1.2 Å","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structures combined with directed evolution and binding validation, multiple orthogonal methods in a single rigorous study","pmids":["31727844"],"is_preprint":false},{"year":2019,"finding":"PD-L2 promotes osteosarcoma invasion and metastasis via tumor cell-intrinsic signaling through the RhoA-ROCK-LIMK2 pathway; PD-L2 knockdown suppresses migration and invasion, inhibits EMT, and reduces autophagy by decreasing beclin-1 expression; beclin-1 in turn regulates RhoA-ROCK-LIMK2 activity.","method":"PD-L2 siRNA knockdown in osteosarcoma cell lines, wound-healing and transwell assays, Western blotting for RhoA-ROCK-LIMK2, EMT markers and beclin-1, orthotopic nude mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro signaling pathway validation plus in vivo metastasis model, single lab","pmids":["30886151"],"is_preprint":false},{"year":2019,"finding":"A super-enhancer (PD-L1L2-SE) located between the CD274 and CD273 genes drives synchronous co-expression of both PD-L1 and PD-L2 in cancer cells; genetic deletion of PD-L1L2-SE profoundly reduces expression of both ligands and abolishes immune evasion, rendering cells sensitive to T cell-mediated killing.","method":"Super-enhancer inhibitor treatment, CRISPR-based genetic deletion of PD-L1L2-SE, RNA-seq, ChIP-seq, T cell killing assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — genetic deletion of regulatory element with direct functional consequence validated by multiple orthogonal methods in one study","pmids":["31825827"],"is_preprint":false},{"year":2019,"finding":"PD-L1L2 super-enhancer region (chr9:5,400,000-5,600,000) forms a topologically associating domain (TAD) around CD274 and CD273 that allows transcription factors STAT3 and IRF1 to be recruited to the PD-L1 locus to drive synchronous transcription of PD-L1 and PD-L2.","method":"Hi-C chromatin conformation analysis, ChIP-seq for STAT3 and IRF1, super-enhancer mapping","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromatin architecture analysis combined with transcription factor ChIP, single lab, review incorporating original data","pmids":["35530130"],"is_preprint":false},{"year":2019,"finding":"PD-L2 expressed on tumor cells in the presence of PD-L1 suppresses tumor antigen-specific CD8+ T cell responses; PD-L2-only tumors confer resistance to anti-PD-L1 mAb that can be overcome by anti-PD-1 mAb or combined anti-PD-L2 mAb; PD-L2 is upregulated on tumor-associated macrophages when mice are treated with anti-PD-L1 mAb.","method":"Syngeneic mouse tumor models with PD-L1/PD-L2 combination knockouts, antibody treatments, flow cytometry for tumor-infiltrating lymphocytes and TAM phenotyping","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple tumor models with genetic manipulation of PD-L1/PD-L2, antibody blockade, and immune phenotyping; single lab","pmids":["31076547"],"is_preprint":false},{"year":2018,"finding":"PD-L2 expression on tumor-associated macrophages (TAMs) becomes functionally relevant for immune suppression specifically when PD-L1 is blocked; anti-PD-L2 mAb treatment showed profound synergy with anti-PD-L1 mAb in anti-tumor responses, whereas anti-PD-L2 mAb alone had minimal effect; bone marrow chimera experiments showed that hematopoietic cell-derived PD-L1 (from BM-derived cells) also contributes to immune suppression.","method":"Anti-PD-L2/PD-L1 mAb treatment in tumor models, bone marrow chimeric mice, flow cytometry for TAM phenotyping","journal":"Cancer immunology, immunotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BM chimera experiments plus antibody combination studies, defined cellular localization of function, single lab","pmids":["30357491"],"is_preprint":false},{"year":2018,"finding":"PD-L2 expression in non-small cell lung cancer is induced intrinsically by activating EGFR mutations and EML4-ALK fusion oncoproteins (suppressed by corresponding TKIs or siRNA knockdown), and extrinsically by IFN-γ via STAT1 signaling; STAT3 and c-FOS transcription factors contribute to both intrinsic and extrinsic pathways of PD-L2 induction.","method":"Stable expression of activated EGFR/EML4-ALK mutants in BEAS-2B cells, TKI treatment, siRNA knockdown of EGFR/ALK/STAT3/c-FOS, IFN-γ stimulation, RT-PCR and flow cytometry","journal":"Journal of thoracic oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function and loss-of-function experiments with multiple oncogene/transcription factor combinations, single lab","pmids":["29596910"],"is_preprint":false},{"year":2020,"finding":"GATA2 is sufficient to drive constitutive PD-L2 (and PD-L1) expression in brain tumor cells and is necessary specifically for PD-L2 expression; GATA2 acts through cis-regulatory regions in the PDCD1LG2 locus; PD-L2 overexpression inhibits neoantigen-specific T cell IFN-γ production.","method":"Luciferase reporter assays with PDCD1LG2 cis-regulatory regions and GATA2 binding site mutations/deletions, flow cytometry for PD-L2 protein, IFN-γ ELISPOT for T cell function","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — luciferase reporter with regulatory element mutation plus functional T cell assay, single lab","pmids":["32493985"],"is_preprint":false},{"year":2021,"finding":"PD-L2 undergoes N-glycosylation by FUT8 (fucosyltransferase), a transcriptional target of STAT3; glycosylated PD-L2 forms a complex with EGFR, activating EGFR/STAT3 signaling and reducing cetuximab binding affinity to EGFR; glycosylation stabilizes PD-L2 by blocking ubiquitin-dependent lysosomal degradation and promotes PD-L2 binding to PD-1 and immune evasion.","method":"Co-immunoprecipitation of PD-L2 with EGFR, N-glycosylation site mutagenesis, FUT8 knockdown, ubiquitination assays, STAT3 inhibitor treatment, in vitro T cell cytotoxicity, in vivo tumor model","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods (Co-IP, mutagenesis, ubiquitination, in vitro/in vivo functional assays) establishing post-translational modification mechanism, single lab","pmids":["34697216"],"is_preprint":false},{"year":2021,"finding":"PD-L2 suppresses T cell signaling by forming coinhibitory microclusters ('PD-1 microclusters') with SHP2 phosphatase at the immunological synapse; PD-L2 competes with PD-L1 for the same PD-1 binding space at TCR microclusters; PD-1 microcluster formation (visible by imaging) is inhibited by specific mAbs.","method":"High-resolution live-cell imaging (super-resolution microscopy), PD-1/PD-L2 microcluster visualization, SHP2 co-localization analysis, competition experiments with PD-L1, mAb functional inhibition assays","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct high-resolution imaging of signaling complexes with functional mAb validation and competition assay, single lab with multiple orthogonal approaches","pmids":["33990697"],"is_preprint":false},{"year":2022,"finding":"PD-L2 controls peripherally induced regulatory T (pTreg) cell numbers and function via PD-1/PD-L2 interactions: PD-L2 deficiency reduces splenic pTreg numbers, decreases IL-10 production, impairs suppressive activity, lowers Foxp3 expression, increases TSDR methylation, and disrupts mitochondrial TCA cycle/ATP production in pTregs; PD-L2high DC transfer restores pTreg numbers in PD-L2KO mice.","method":"PD-L2-/- mouse model, in vitro iTreg generation, TSDR methylation analysis, mitochondrial metabolic assays (TCA cycle, ATP), adoptive transfer of PD-L2high DCs, pyruvate rescue experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple orthogonal mechanistic readouts (epigenetic, metabolic, functional), DC transfer rescue, in vitro and in vivo validation","pmids":["36045140"],"is_preprint":false},{"year":2023,"finding":"The gut microbiome downregulates PD-L2 expression and its binding partner RGMb to promote anti-tumor immunity; antibody-mediated blockade of the PD-L2-RGMb pathway (separate from PD-1) combined with anti-PD-1 or anti-PD-L1 promotes anti-tumor responses in multiple tumor models resistant to PD-1/PD-L1 blockade alone, including germ-free and antibiotic-treated mice.","method":"PD-L2 and RGMb antibody blockade in germ-free/antibiotic-treated/conventionally colonized mouse tumor models, conditional RGMb deletion in T cells, fecal transplant experiments, gene expression analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic conditional KO combined with antibody blockade across multiple independent tumor models and germ-free conditions, identifying mechanistic pathway","pmids":["37138075"],"is_preprint":false},{"year":2024,"finding":"PD-L2 is upregulated upon induction of cellular senescence in cancer cells (identified by unbiased proteomics); PD-L2 is required for senescent cancer cells to evade immune clearance—PD-L2-deficient senescent cells are rapidly eliminated; PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo CD8 T cell-driven regression after chemotherapy.","method":"Proteomics screen, PD-L2 knockout in cancer cell lines, murine tumor models with chemotherapy, flow cytometry for immune cell infiltrates (MDSC, CD8 T cells), senescence assays","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined cellular phenotype and mechanism (MDSC recruitment, CD8 T cell response), multiple tumor models, unbiased discovery approach","pmids":["38267628"],"is_preprint":false},{"year":2017,"finding":"PD-L2 regulates B-1 cell natural antibody production against phosphorylcholine (PC) via an IL-5-dependent mechanism: B-1 cell-intrinsic PD-L2 expression inhibits IL-5 production by T cells, which in turn limits B-1 cell plasmablast differentiation and PC-specific IgM production; PD-L2 mAb blockade increased IL-5+ T cells and CD138/Blimp1 expression on B-1 cells.","method":"PD-L2-/- mice and irradiated chimeras reconstituted with PD-L2-/- B cells, in vitro B-1 cell culture with PD-L2 mAb blockade, IL-5 neutralization and STAT5 inhibition, flow cytometry, ELISA","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific chimera experiments plus in vitro blockade with pathway rescue, single lab","pmids":["28768724"],"is_preprint":false},{"year":2010,"finding":"PD-L2 induction on dendritic cells by Mycobacterium avium is mediated through the TLR2-p38 MAPK signaling pathway and requires IL-10 production; M. avium-exposed DCs with PD-L2 expression impair activation of BCG-specific T cells through PD-1:PD-L interactions.","method":"Bone marrow-derived DC stimulation with M. avium, TLR2 knockdown, p38 MAPK inhibition, IL-10 neutralization, flow cytometry for PD-L2, antigen-specific T cell activation assays","journal":"Tuberculosis (Edinburgh, Scotland)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection with inhibitors and neutralization combined with functional T cell assays, single lab","pmids":["21147037"],"is_preprint":false},{"year":2024,"finding":"PD-L2 is predominantly expressed on the surface of exosomes derived from clear cell renal cell carcinoma (ccRCC) cells; tumor-derived exosomal PD-L2 (TDE-PD-L2) suppresses T cell function in a PD-1-dependent manner, increasing regulatory T cells and decreasing cytotoxic CD8+ T cells both in tumor-infiltrating and splenic compartments; anti-PD-L2 antibody restores immune function.","method":"Exosome isolation and characterization, flow cytometry for surface PD-L2 on exosomes, in vitro T cell co-culture assays, in vivo tumor models with immune-competent vs immunodeficient mice, antibody blockade","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — exosome characterization with PD-1-dependent functional validation in vitro and in vivo, single lab","pmids":["39511147"],"is_preprint":false},{"year":2021,"finding":"In gastric cancer, tumor cell-derived G-CSF induces FasL and PD-L2 expression on neutrophils via the JAK-STAT3 signaling pathway, while Th17 cell-derived IL-17A induces FasL and PD-L2 via ERK-NF-κB signaling; FasL+ PD-L2+ neutrophils acquire immunosuppressive functions that suppress tumor-specific CD8+ T cells in a manner reversible by blocking FasL and PD-L2.","method":"Cytokine stimulation of neutrophils, JAK/STAT3 and ERK/NF-κB inhibitor assays, flow cytometry for FasL and PD-L2, co-culture with CD8+ T cells, in vivo tumor growth assays","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway inhibitor experiments defining signaling cascade, in vitro and in vivo functional validation, single lab","pmids":["34957697"],"is_preprint":false},{"year":2024,"finding":"Matrix stiffness-induced PD-L2 suppresses ferroptosis in hepatocellular carcinoma: SMYD3 (a histone methyltransferase) activated by matrix stiffening drives H3K4me3-mediated transcriptional induction of PD-L2, which then acts as an RNA-binding protein to enhance mRNA stability of FTL (ferritin light chain), elevating FTL protein and inhibiting xCT (SLC7A11)-mediated ferroptosis.","method":"SMYD3 knockdown/overexpression, H3K4me3 ChIP, PD-L2 knockdown on stiff substrates, ferroptosis assays (cell viability, ferrous iron, mitochondrial pathology), FTL mRNA stability assays, in vivo tumor model","journal":"Journal of advanced research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional ferroptosis assays and RNA stability experiments, multiple orthogonal methods; single lab","pmids":["39159723"],"is_preprint":false},{"year":2024,"finding":"SPHK1/S1P signaling promotes PD-L2 expression in bladder cancer via Akt/β-catenin activation; PD-L2 then interacts with c-Src (co-immunoprecipitation confirmed), which further activates FAK, promoting cancer cell invasion and migration.","method":"CRISPR/Cas9 SPHK1 KO and constitutive activation, PD-L2 knockdown/overexpression, co-immunoprecipitation of PD-L2 with c-Src, FAK phosphorylation assays, invasion/migration assays, in vivo tumor model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing PD-L2/c-Src interaction, genetic manipulation with functional readouts, in vitro and in vivo validation, single lab","pmids":["39284838"],"is_preprint":false},{"year":2019,"finding":"EBV microRNA BHRF1-2-5p binds to the 3'UTR of PD-L2 (and PD-L1) mRNA to reduce their surface protein expression, acting as a counterregulatory mechanism to fine-tune LMP1-driven amplification of PD-L2 expression in EBV+ DLBCL.","method":"3'UTR reporter assays, EBV-infected B cell differentiation model, EBV miR BHRF1-2-5p overexpression/inhibition, flow cytometry for surface PD-L2","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional 3'UTR validation and miRNA manipulation with protein level readout, single lab","pmids":["31856276"],"is_preprint":false},{"year":2019,"finding":"Topical siRNA silencing of PD-L2 in cutaneous dendritic cells inhibits elicitation of contact hypersensitivity by suppressing early pro-inflammatory cytokine expression and migration of hapten-carrying DCs to lymph nodes; this effect is independent of PD-1/PD-L1 but dependent on local memory T cells, suggesting PD-L2 acts as a costimulator in this context.","method":"Topical siRNA application, anti-PD-L2 mAb injection, CHS assay in PD-1/PD-L1 double KO mice, T cell transfer experiments, cytokine measurement","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown and antibody blockade with PD-1/PD-L1 KO controls, multiple functional readouts, single lab","pmids":["30978356"],"is_preprint":false}],"current_model":"PD-L2 (PDCD1LG2) is a cell-surface ligand that binds PD-1 with ~3-fold higher affinity than PD-L1 (due to a C-D 'latch' and W110 'elbow' in its IgV domain) and suppresses T cell activation by forming PD-1 microclusters that recruit SHP-2 phosphatase to dephosphorylate TCR/CD3 signaling components, thereby inhibiting PI3K/AKT and ERK/MAPK pathways; its expression is transcriptionally co-regulated with PD-L1 by a shared super-enhancer (PD-L1L2-SE) and by STAT3/IRF1 downstream of IFN-β/γ, NF-κB, and oncogenic EGFR/ALK signaling, and post-translationally stabilized by FUT8-mediated N-glycosylation; beyond PD-1, PD-L2 also signals through RGMb to costimulate Th1 responses and, in a cell-intrinsic capacity, promotes tumor metastasis via RhoA-ROCK-LIMK2, suppresses ferroptosis via SMYD3/H3K4me3-FTL stabilization, and interacts with c-Src/FAK to drive invasion, while on immune cells it limits pTreg Foxp3 stability through metabolic (TCA cycle/ATP) regulation, regulates B-1 cell natural antibody production via IL-5 suppression, and is upregulated on therapy-induced senescent tumor cells to mediate MDSC recruitment and immune evasion."},"narrative":{"mechanistic_narrative":"PDCD1LG2 (PD-L2/B7-DC) is a cell-surface immunoglobulin-superfamily ligand that functions as a coinhibitory checkpoint on antigen-presenting cells, restraining T cell activation by engaging PD-1 [PMID:11224527, PMID:16864790]. Through its IgV domain it binds PD-1 with roughly 3-fold higher affinity than PD-L1, a property conferred by a C-D β-strand 'latch' and a W110 'elbow' that respectively enhance affinity and limit engagement duration, and the two ligands compete for the same binding site on PD-1 [PMID:20587542, PMID:31882544, PMID:31727844]. Engagement triggers PD-1 microcluster formation at the immunological synapse that recruits SHP-2 phosphatase, suppressing TCR-driven PI3K/AKT and ERK/MAPK signaling and arresting proliferation and cytokine production [PMID:16278812, PMID:33990697]. Its expression is differentially controlled relative to PD-L1: it is induced by IL-4/STAT6 during alternative macrophage activation, by NF-κB, and equally by IFN-β and IFN-γ through direct promoter binding of IRF1 and STAT3 [PMID:12697896, PMID:14515254, PMID:28494868]. In cancer, PD-L2 is co-regulated with PD-L1 by a shared super-enhancer organized within a TAD that recruits STAT3/IRF1 to drive synchronous transcription, is driven by oncogenic EGFR/ALK signaling, and is post-translationally stabilized by FUT8-mediated N-glycosylation that blocks lysosomal degradation and promotes EGFR complex formation [PMID:31825827, PMID:35530130, PMID:29596910, PMID:34697216]; loss of these ligands restores T cell-mediated tumor killing [PMID:31825827, PMID:38267628]. Beyond PD-1, PD-L2 binds a second receptor, RGMb, through which it costimulates Th1 responses, and blockade of the PD-L2-RGMb axis sensitizes PD-1/PD-L1-resistant tumors [PMID:28479601, PMID:37138075]. PD-L2 also exerts cell-intrinsic, receptor-independent functions in tumor cells, promoting invasion and metastasis via RhoA-ROCK-LIMK2 and c-Src/FAK signaling and suppressing ferroptosis by acting as an RNA-binding protein that stabilizes FTL mRNA [PMID:30886151, PMID:39159723, PMID:39284838]. On immune cells it sustains peripherally induced Treg numbers and function through metabolic regulation and limits B-1 cell natural antibody production via IL-5 suppression [PMID:36045140, PMID:28768724].","teleology":[{"year":2001,"claim":"Established that PD-1 has a second ligand beyond PD-L1 and that this ligand delivers an inhibitory signal to T cells, defining PD-L2 as a coinhibitory checkpoint molecule.","evidence":"Cell-based binding and T cell proliferation/cytokine assays with Western blotting for SHP-2 phosphorylation","pmids":["11224527"],"confidence":"High","gaps":["Did not resolve structural basis of PD-1 binding","Downstream signaling beyond SHP-2 recruitment not mapped"]},{"year":2003,"claim":"Defined PD-L2 as differentially regulated from PD-L1, induced by Th2/IL-4-STAT6 and NF-κB rather than the classical activation pathway, indicating context-specific deployment of the two ligands.","evidence":"Macrophage and dendritic cell stimulation in STAT6-/-, STAT1-/-, and NF-κB p50-/-p65+/- knockouts with flow cytometry","pmids":["12697896","14515254"],"confidence":"Medium","gaps":["Promoter elements bound by these factors not mapped","Human regulation not directly tested"]},{"year":2003,"claim":"Provided early evidence for a PD-1-independent costimulatory function, hinting at a second receptor for PD-L2 long before its identification.","evidence":"Tumor rejection and cytotoxicity assays using PD-1-/- cells","pmids":["12810690"],"confidence":"Medium","gaps":["Identity of the second receptor unknown at the time","Single-lab finding"]},{"year":2005,"claim":"Connected PD-L2/PD-1 engagement to specific intracellular cascades, showing rapid AKT and delayed ERK suppression downstream of SHP-2 activation in human T cells.","evidence":"Human T cell assays with phospho-AKT/ERK blotting, SHP-2 phosphatase activity, and PD-1 co-IP","pmids":["16278812"],"confidence":"Medium","gaps":["Spatial organization of signaling not resolved","Single lab"]},{"year":2006,"claim":"Genetic knockout established that PD-L2 negatively regulates T cell activation and oral tolerance in a PD-1-dependent manner in vivo.","evidence":"PDL2-/- mice with in vitro/in vivo T cell activation and tolerance assays plus PD-1-dependence tests","pmids":["16864790"],"confidence":"High","gaps":["Tissue-specific contributions not dissected","Did not address non-PD-1 receptor"]},{"year":2009,"claim":"Demonstrated that PD-L1 and PD-L2 can play opposing roles in tissue immunity, distinguishing PD-L2's function from PD-L1 in airway disease.","evidence":"Reciprocal PD-L1-/- and PD-L2-/- mouse asthma models with iNKT transfer and in vitro blockade","pmids":["19741598"],"confidence":"High","gaps":["Molecular basis of opposing effects unresolved","Receptor mediating effect not defined"]},{"year":2010,"claim":"Resolved the binding kinetics relationship between PD-L1 and PD-L2 for PD-1, showing comparable affinity but distinct mechanisms and shared binding site.","evidence":"SPR, cell-surface binding, and competition assays with blocking mAbs","pmids":["20587542"],"confidence":"High","gaps":["Structural determinants of kinetic differences not identified","Functional consequence of kinetic distinction untested"]},{"year":2017,"claim":"Identified RGMb as the long-sought second receptor for PD-L2 and showed it mediates PD-1-independent Th1 costimulation, explaining earlier PD-1-independent observations.","evidence":"K113S PD-1-binding-deficient PD-L2 mutant in binding and costimulation assays plus a murine asthma model","pmids":["28479601"],"confidence":"Medium","gaps":["RGMb downstream signaling not mapped","Single lab"]},{"year":2017,"claim":"Established the dominant interferon-responsive transcriptional control of PD-L2 by IRF1 and STAT3, distinguishing it from the STAT1-centric regulation of PD-L1.","evidence":"siRNA knockdown of JAK/STAT/IRF components and ChIP at the PD-L2 promoter in melanoma cells","pmids":["28494868"],"confidence":"High","gaps":["Did not address chromatin architecture","Cooperation with PD-L1 locus not yet shown"]},{"year":2019,"claim":"Defined the structural basis of PD-L2's affinity advantage, attributing the net 3-fold higher PD-1 affinity to a C-D latch and W110 elbow, and crystallized the human PD-1/PD-L2 complex.","evidence":"SPR with systematic mutagenesis, phylogenetic analysis, deep mutational scanning, and X-ray crystallography of the PD-1/PD-L2 complex","pmids":["31882544","31727844"],"confidence":"High","gaps":["Functional consequence of the affinity advantage in vivo not quantified","Required a high-affinity PD-1 mutant for crystallization"]},{"year":2019,"claim":"Showed that PD-L1 and PD-L2 are coordinately driven by a shared super-enhancer organized into a TAD recruiting STAT3/IRF1, linking the transcriptional logic of both ligands.","evidence":"CRISPR deletion of PD-L1L2-SE, RNA-seq, ChIP-seq, Hi-C, and T cell killing assays","pmids":["31825827","35530130"],"confidence":"High","gaps":["Upstream signals activating the super-enhancer not fully mapped","Generalizability across tumor types not established"]},{"year":2019,"claim":"Revealed tumor-cell-intrinsic, receptor-independent functions of PD-L2, driving invasion and metastasis through RhoA-ROCK-LIMK2 and autophagy regulation.","evidence":"PD-L2 knockdown in osteosarcoma lines with migration/invasion assays, pathway blotting, and orthotopic mouse model","pmids":["30886151"],"confidence":"Medium","gaps":["How surface PD-L2 transduces an intracellular signal unclear","Single lab and tumor type"]},{"year":2018,"claim":"Identified oncogenic drivers (EGFR mutations, EML4-ALK) and the macrophage compartment as sources of PD-L2 that become functionally important when PD-L1 is blocked, rationalizing combination checkpoint blockade.","evidence":"Oncogene gain/loss-of-function in lung cells, TKI/siRNA, and antibody combination plus BM chimera tumor experiments","pmids":["29596910","30357491"],"confidence":"Medium","gaps":["Relative contribution of tumor vs myeloid PD-L2 not quantified across cancers","Single lab per study"]},{"year":2021,"claim":"Defined the spatial signaling mechanism, showing PD-L2 nucleates PD-1/SHP2 coinhibitory microclusters that compete with PD-L1 at TCR microclusters.","evidence":"Super-resolution live-cell imaging of PD-1 microclusters with SHP2 co-localization, competition, and mAb inhibition","pmids":["33990697"],"confidence":"High","gaps":["Quantitative threshold for inhibition not defined","Single lab"]},{"year":2021,"claim":"Established post-translational control of PD-L2 by FUT8-mediated N-glycosylation that stabilizes the protein, links it to EGFR signaling, and promotes immune evasion.","evidence":"Co-IP, glycosylation-site mutagenesis, FUT8 knockdown, ubiquitination and cytotoxicity assays, and in vivo tumor model","pmids":["34697216"],"confidence":"High","gaps":["Glycan structures not fully characterized","Single lab"]},{"year":2022,"claim":"Revealed an immune-intrinsic role for PD-L2 in sustaining peripheral Treg numbers and function through epigenetic and metabolic regulation of Foxp3 stability.","evidence":"PD-L2-/- mice with iTreg generation, TSDR methylation, mitochondrial metabolic assays, and DC transfer/pyruvate rescue","pmids":["36045140"],"confidence":"High","gaps":["Direct link between PD-1 signaling and Treg metabolism mechanistically incomplete","Human relevance not tested"]},{"year":2023,"claim":"Showed the gut microbiome modulates the PD-L2-RGMb axis and that blocking it overcomes resistance to PD-1/PD-L1 therapy, establishing therapeutic relevance of the second-receptor pathway.","evidence":"Antibody blockade in germ-free/antibiotic/colonized tumor models, conditional T cell RGMb deletion, and fecal transplant","pmids":["37138075"],"confidence":"High","gaps":["Microbial species and metabolites responsible not fully defined","RGMb downstream signaling incomplete"]},{"year":2024,"claim":"Expanded PD-L2's intrinsic repertoire by showing it acts as an RNA-binding protein to stabilize FTL mRNA and suppress ferroptosis, and by linking it to senescence-associated immune evasion and exosomal/c-Src-FAK invasion programs.","evidence":"SMYD3/H3K4me3 ChIP and ferroptosis assays, FTL mRNA stability assays, proteomics-based senescence screen with KO tumor models, exosome characterization, and PD-L2/c-Src Co-IP","pmids":["39159723","38267628","39511147","39284838"],"confidence":"Medium","gaps":["RNA-binding mechanism of a surface ligand structurally unexplained","Findings are single-lab and tumor-type specific"]},{"year":null,"claim":"How a cell-surface ligand executes its diverse cell-intrinsic functions (RNA binding, cytoskeletal/invasion signaling) and how these reconcile with its canonical surface coinhibitory role remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking surface ligand and intracellular functions","Topology enabling intracellular RNA binding unexplained","RGMb downstream signaling cascade undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,5,12]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[8,13,14]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[31]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,9,23]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[29]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,5,23]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,23,32]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[11,16,17]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[22]}],"complexes":[],"partners":["PDCD1","RGMB","SHP2","EGFR","FUT8","C-SRC","FTL"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BQ51","full_name":"Programmed cell death 1 ligand 2","aliases":["Butyrophilin B7-DC","B7-DC"],"length_aa":273,"mass_kda":31.0,"function":"Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11224527, PubMed:12538684). Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production (PubMed:11224527)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9BQ51/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDCD1LG2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDCD1LG2","total_profiled":1310},"omim":[{"mim_id":"618534","title":"IMMUNODEFICIENCY 64 WITH LYMPHOPROLIFERATION; IMD64","url":"https://www.omim.org/entry/618534"},{"mim_id":"605723","title":"PROGRAMMED CELL DEATH 1 LIGAND 2; PDCD1LG2","url":"https://www.omim.org/entry/605723"},{"mim_id":"605402","title":"CD274 MOLECULE; CD274","url":"https://www.omim.org/entry/605402"},{"mim_id":"604459","title":"INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 3; IRAK3","url":"https://www.omim.org/entry/604459"},{"mim_id":"603962","title":"RAS GUANYL NUCLEOTIDE-RELEASING PROTEIN 1; RASGRP1","url":"https://www.omim.org/entry/603962"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Cytosol","reliability":"Uncertain"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":14.3}],"url":"https://www.proteinatlas.org/search/PDCD1LG2"},"hgnc":{"alias_symbol":["PD-L2","Btdc","PDL2","bA574F11.2","CD273","B7-DC","B7DC"],"prev_symbol":[]},"alphafold":{"accession":"Q9BQ51","domains":[{"cath_id":"2.60.40.10","chopping":"18-121","consensus_level":"high","plddt":91.1681,"start":18,"end":121},{"cath_id":"2.60.40.10","chopping":"127-209","consensus_level":"high","plddt":95.7228,"start":127,"end":209}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BQ51","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BQ51-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BQ51-F1-predicted_aligned_error_v6.png","plddt_mean":86.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDCD1LG2","jax_strain_url":"https://www.jax.org/strain/search?query=PDCD1LG2"},"sequence":{"accession":"Q9BQ51","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BQ51.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BQ51/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BQ51"}},"corpus_meta":[{"pmid":"11224527","id":"PMC_11224527","title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation.","date":"2001","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11224527","citation_count":2352,"is_preprint":false},{"pmid":"28494868","id":"PMC_28494868","title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28494868","citation_count":1477,"is_preprint":false},{"pmid":"27069084","id":"PMC_27069084","title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.","date":"2016","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27069084","citation_count":653,"is_preprint":false},{"pmid":"24270737","id":"PMC_24270737","title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.","date":"2013","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/24270737","citation_count":591,"is_preprint":false},{"pmid":"14515254","id":"PMC_14515254","title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14515254","citation_count":532,"is_preprint":false},{"pmid":"12697896","id":"PMC_12697896","title":"PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12697896","citation_count":522,"is_preprint":false},{"pmid":"28619999","id":"PMC_28619999","title":"PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28619999","citation_count":494,"is_preprint":false},{"pmid":"28768162","id":"PMC_28768162","title":"Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.","date":"2017","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/28768162","citation_count":298,"is_preprint":false},{"pmid":"20587542","id":"PMC_20587542","title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.","date":"2010","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20587542","citation_count":192,"is_preprint":false},{"pmid":"37138075","id":"PMC_37138075","title":"Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37138075","citation_count":158,"is_preprint":false},{"pmid":"19741598","id":"PMC_19741598","title":"PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.","date":"2009","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19741598","citation_count":158,"is_preprint":false},{"pmid":"17182110","id":"PMC_17182110","title":"PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.","date":"2006","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/17182110","citation_count":152,"is_preprint":false},{"pmid":"16864790","id":"PMC_16864790","title":"Regulation of T cell activation and tolerance by PDL2.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16864790","citation_count":134,"is_preprint":false},{"pmid":"25025450","id":"PMC_25025450","title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25025450","citation_count":126,"is_preprint":false},{"pmid":"29399387","id":"PMC_29399387","title":"Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.","date":"2017","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/29399387","citation_count":123,"is_preprint":false},{"pmid":"12810690","id":"PMC_12810690","title":"B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12810690","citation_count":123,"is_preprint":false},{"pmid":"26081225","id":"PMC_26081225","title":"Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.","date":"2015","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/26081225","citation_count":121,"is_preprint":false},{"pmid":"20722638","id":"PMC_20722638","title":"Role of PD-L1 and PD-L2 in allergic diseases and asthma.","date":"2010","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/20722638","citation_count":104,"is_preprint":false},{"pmid":"27050074","id":"PMC_27050074","title":"Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27050074","citation_count":100,"is_preprint":false},{"pmid":"16278812","id":"PMC_16278812","title":"PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16278812","citation_count":99,"is_preprint":false},{"pmid":"21752471","id":"PMC_21752471","title":"PD-L2 is expressed on activated human T cells and regulates their function.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21752471","citation_count":96,"is_preprint":false},{"pmid":"38267628","id":"PMC_38267628","title":"The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2.","date":"2024","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38267628","citation_count":90,"is_preprint":false},{"pmid":"35530130","id":"PMC_35530130","title":"The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35530130","citation_count":88,"is_preprint":false},{"pmid":"33219943","id":"PMC_33219943","title":"Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.","date":"2020","source":"Hepatology international","url":"https://pubmed.ncbi.nlm.nih.gov/33219943","citation_count":85,"is_preprint":false},{"pmid":"36522474","id":"PMC_36522474","title":"Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36522474","citation_count":83,"is_preprint":false},{"pmid":"18811584","id":"PMC_18811584","title":"Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses.","date":"2008","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18811584","citation_count":83,"is_preprint":false},{"pmid":"31076547","id":"PMC_31076547","title":"Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31076547","citation_count":80,"is_preprint":false},{"pmid":"33424844","id":"PMC_33424844","title":"PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33424844","citation_count":80,"is_preprint":false},{"pmid":"27312343","id":"PMC_27312343","title":"Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.","date":"2016","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/27312343","citation_count":78,"is_preprint":false},{"pmid":"34697216","id":"PMC_34697216","title":"PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34697216","citation_count":77,"is_preprint":false},{"pmid":"29254220","id":"PMC_29254220","title":"Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29254220","citation_count":76,"is_preprint":false},{"pmid":"31882544","id":"PMC_31882544","title":"The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31882544","citation_count":71,"is_preprint":false},{"pmid":"31159869","id":"PMC_31159869","title":"PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.","date":"2019","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31159869","citation_count":68,"is_preprint":false},{"pmid":"30886151","id":"PMC_30886151","title":"Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30886151","citation_count":68,"is_preprint":false},{"pmid":"17311651","id":"PMC_17311651","title":"Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases.","date":"2007","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17311651","citation_count":67,"is_preprint":false},{"pmid":"16358363","id":"PMC_16358363","title":"PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16358363","citation_count":67,"is_preprint":false},{"pmid":"25349132","id":"PMC_25349132","title":"PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.","date":"2014","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25349132","citation_count":66,"is_preprint":false},{"pmid":"30996253","id":"PMC_30996253","title":"JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.","date":"2019","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/30996253","citation_count":60,"is_preprint":false},{"pmid":"30531969","id":"PMC_30531969","title":"PDL2+ CD11b+ dermal dendritic cells capture topical antigen through hair follicles to prime LAP+ Tregs.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30531969","citation_count":60,"is_preprint":false},{"pmid":"30891423","id":"PMC_30891423","title":"Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30891423","citation_count":57,"is_preprint":false},{"pmid":"31464648","id":"PMC_31464648","title":"A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.","date":"2019","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31464648","citation_count":57,"is_preprint":false},{"pmid":"30357491","id":"PMC_30357491","title":"Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.","date":"2018","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/30357491","citation_count":57,"is_preprint":false},{"pmid":"31856276","id":"PMC_31856276","title":"EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31856276","citation_count":56,"is_preprint":false},{"pmid":"31825827","id":"PMC_31825827","title":"A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31825827","citation_count":54,"is_preprint":false},{"pmid":"27503244","id":"PMC_27503244","title":"The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.","date":"2016","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27503244","citation_count":52,"is_preprint":false},{"pmid":"31727844","id":"PMC_31727844","title":"A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31727844","citation_count":52,"is_preprint":false},{"pmid":"34011561","id":"PMC_34011561","title":"Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.","date":"2021","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/34011561","citation_count":52,"is_preprint":false},{"pmid":"29416641","id":"PMC_29416641","title":"PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29416641","citation_count":51,"is_preprint":false},{"pmid":"29038297","id":"PMC_29038297","title":"Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.","date":"2017","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/29038297","citation_count":49,"is_preprint":false},{"pmid":"31553906","id":"PMC_31553906","title":"Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31553906","citation_count":47,"is_preprint":false},{"pmid":"28488345","id":"PMC_28488345","title":"Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.","date":"2017","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28488345","citation_count":47,"is_preprint":false},{"pmid":"18662368","id":"PMC_18662368","title":"PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation.","date":"2008","source":"Transplant international : official journal of the European Society for Organ Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/18662368","citation_count":45,"is_preprint":false},{"pmid":"28479601","id":"PMC_28479601","title":"B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb.","date":"2017","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28479601","citation_count":43,"is_preprint":false},{"pmid":"23149662","id":"PMC_23149662","title":"PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production.","date":"2012","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23149662","citation_count":43,"is_preprint":false},{"pmid":"30546952","id":"PMC_30546952","title":"Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30546952","citation_count":41,"is_preprint":false},{"pmid":"32367440","id":"PMC_32367440","title":"Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer.","date":"2020","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/32367440","citation_count":39,"is_preprint":false},{"pmid":"32248797","id":"PMC_32248797","title":"PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32248797","citation_count":38,"is_preprint":false},{"pmid":"34957697","id":"PMC_34957697","title":"FasL+ PD-L2+ Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34957697","citation_count":37,"is_preprint":false},{"pmid":"36045140","id":"PMC_36045140","title":"PD-L2 controls peripherally induced regulatory T cells by maintaining metabolic activity and Foxp3 stability.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36045140","citation_count":34,"is_preprint":false},{"pmid":"29596910","id":"PMC_29596910","title":"Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.","date":"2018","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29596910","citation_count":34,"is_preprint":false},{"pmid":"28768724","id":"PMC_28768724","title":"PD-L2 Regulates B-1 Cell Antibody Production against Phosphorylcholine through an IL-5-Dependent Mechanism.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28768724","citation_count":33,"is_preprint":false},{"pmid":"30033844","id":"PMC_30033844","title":"Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.","date":"2018","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/30033844","citation_count":31,"is_preprint":false},{"pmid":"27069956","id":"PMC_27069956","title":"PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.","date":"2016","source":"American journal of clinical and experimental urology","url":"https://pubmed.ncbi.nlm.nih.gov/27069956","citation_count":26,"is_preprint":false},{"pmid":"24376539","id":"PMC_24376539","title":"TLR2 directing PD-L2 expression inhibit T cells response in Schistosoma japonicum infection.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376539","citation_count":25,"is_preprint":false},{"pmid":"30559738","id":"PMC_30559738","title":"Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30559738","citation_count":24,"is_preprint":false},{"pmid":"38956724","id":"PMC_38956724","title":"Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity.","date":"2024","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38956724","citation_count":24,"is_preprint":false},{"pmid":"33990697","id":"PMC_33990697","title":"PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33990697","citation_count":23,"is_preprint":false},{"pmid":"36672315","id":"PMC_36672315","title":"Radiomic Analysis Based on Magnetic Resonance Imaging for Predicting PD-L2 Expression in Hepatocellular Carcinoma.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36672315","citation_count":23,"is_preprint":false},{"pmid":"30464512","id":"PMC_30464512","title":"Clinicopathological analysis of PD-L2 expression in colorectal cancer.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30464512","citation_count":22,"is_preprint":false},{"pmid":"32493985","id":"PMC_32493985","title":"GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32493985","citation_count":21,"is_preprint":false},{"pmid":"28570665","id":"PMC_28570665","title":"PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28570665","citation_count":21,"is_preprint":false},{"pmid":"29890018","id":"PMC_29890018","title":"High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.","date":"2018","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/29890018","citation_count":21,"is_preprint":false},{"pmid":"27783986","id":"PMC_27783986","title":"PD-L2 negatively regulates Th1-mediated immunopathology during Fasciola hepatica infection.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27783986","citation_count":20,"is_preprint":false},{"pmid":"21147037","id":"PMC_21147037","title":"PD-L2 induction on dendritic cells exposed to Mycobacterium avium downregulates BCG-specific T cell response.","date":"2010","source":"Tuberculosis (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/21147037","citation_count":20,"is_preprint":false},{"pmid":"39511147","id":"PMC_39511147","title":"PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39511147","citation_count":19,"is_preprint":false},{"pmid":"30821175","id":"PMC_30821175","title":"Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas.","date":"2019","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/30821175","citation_count":19,"is_preprint":false},{"pmid":"34773342","id":"PMC_34773342","title":"PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34773342","citation_count":19,"is_preprint":false},{"pmid":"30524881","id":"PMC_30524881","title":"PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30524881","citation_count":19,"is_preprint":false},{"pmid":"37828429","id":"PMC_37828429","title":"Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37828429","citation_count":18,"is_preprint":false},{"pmid":"34347720","id":"PMC_34347720","title":"Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.","date":"2021","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/34347720","citation_count":17,"is_preprint":false},{"pmid":"30864556","id":"PMC_30864556","title":"Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients.","date":"2019","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/30864556","citation_count":17,"is_preprint":false},{"pmid":"35569724","id":"PMC_35569724","title":"Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology.","date":"2022","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35569724","citation_count":16,"is_preprint":false},{"pmid":"33404124","id":"PMC_33404124","title":"ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/33404124","citation_count":16,"is_preprint":false},{"pmid":"39159723","id":"PMC_39159723","title":"Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/39159723","citation_count":15,"is_preprint":false},{"pmid":"39284838","id":"PMC_39284838","title":"SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39284838","citation_count":15,"is_preprint":false},{"pmid":"34832887","id":"PMC_34832887","title":"The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia.","date":"2021","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34832887","citation_count":15,"is_preprint":false},{"pmid":"35366112","id":"PMC_35366112","title":"Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.","date":"2022","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35366112","citation_count":15,"is_preprint":false},{"pmid":"32151519","id":"PMC_32151519","title":"Programmed death-ligand 2 (PD-L2) expression in bladder cancer.","date":"2020","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32151519","citation_count":14,"is_preprint":false},{"pmid":"36232911","id":"PMC_36232911","title":"Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36232911","citation_count":13,"is_preprint":false},{"pmid":"32259363","id":"PMC_32259363","title":"Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus.","date":"2020","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32259363","citation_count":13,"is_preprint":false},{"pmid":"24664538","id":"PMC_24664538","title":"Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias.","date":"2014","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24664538","citation_count":13,"is_preprint":false},{"pmid":"35037417","id":"PMC_35037417","title":"PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.","date":"2022","source":"The journal of pathology. Clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/35037417","citation_count":13,"is_preprint":false},{"pmid":"37006239","id":"PMC_37006239","title":"Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37006239","citation_count":12,"is_preprint":false},{"pmid":"28777458","id":"PMC_28777458","title":"Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28777458","citation_count":12,"is_preprint":false},{"pmid":"30978356","id":"PMC_30978356","title":"Silencing of PD-L2/B7-DC by Topical Application of Small Interfering RNA Inhibits Elicitation of Contact Hypersensitivity.","date":"2019","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30978356","citation_count":12,"is_preprint":false},{"pmid":"32915645","id":"PMC_32915645","title":"Lower PDL1, PDL2, and AXL Expression on Lung Myeloid Cells Suggests Inflammatory Bias in Smoking and Chronic Obstructive Pulmonary Disease.","date":"2020","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32915645","citation_count":11,"is_preprint":false},{"pmid":"36652667","id":"PMC_36652667","title":"High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer.","date":"2023","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36652667","citation_count":11,"is_preprint":false},{"pmid":"34382413","id":"PMC_34382413","title":"DNA Methylation Patterns in the HLA-DPB1 and PDCD1LG2 Gene Regions in Patients with Autoimmune Thyroiditis from Different Water Iodine Areas.","date":"2021","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/34382413","citation_count":11,"is_preprint":false},{"pmid":"32684057","id":"PMC_32684057","title":"PD-1, CTLA4, PD-L1 and PD-L2 DNA methylation in papillary thyroid carcinoma.","date":"2020","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/32684057","citation_count":11,"is_preprint":false},{"pmid":"34289871","id":"PMC_34289871","title":"Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.","date":"2021","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/34289871","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56322,"output_tokens":9680,"usd":0.157083,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19662,"output_tokens":5455,"usd":0.117343,"stage2_stop_reason":"end_turn"},"total_usd":0.274426,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"PD-L2 was identified as a second ligand for PD-1 that inhibits T cell activation: engagement of PD-1 by PD-L2 dramatically inhibits TCR-mediated proliferation and cytokine production by CD4+ T cells, leads to cell cycle arrest in G0/G1, and ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2.\",\n      \"method\": \"Cell-based binding assays, T cell proliferation and cytokine assays, Western blotting for SHP-2 phosphorylation\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — original identification paper with multiple orthogonal functional assays; widely replicated across many subsequent studies\",\n      \"pmids\": [\"11224527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PD-L2 expression depends on IL-4Rα and STAT6 signaling, whereas PD-L1 expression depends on TLR4 and STAT1, demonstrating that PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 signals on macrophages; PD-L2 is induced by IL-4 (alternative activation) but not by LPS/IFN-γ (classical activation).\",\n      \"method\": \"Macrophage stimulation assays, STAT6-/- and STAT1-/- knockout cells, flow cytometry for surface expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal knockout validation with defined signaling pathway, replicated in multiple macrophage populations\",\n      \"pmids\": [\"12697896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PD-L2 (B7-DC) can promote CD8 T cell-mediated tumor rejection via a PD-1-independent mechanism: B7-DC binds to PD-1-/- cells and enhances T cell killing, indicating a second receptor/pathway for B7-DC costimulation.\",\n      \"method\": \"Tumor rejection assays in PD-1-/- mice, T cell cytotoxicity assays, binding studies on PD-1-deficient cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo tumor rejection and in vitro binding with PD-1 KO cells, single lab\",\n      \"pmids\": [\"12810690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PD-L2 transcription is regulated through NF-κB (p50/p65): PD-L2 expression was dramatically reduced in NF-κB p50-/-p65+/- dendritic cells, whereas PD-L1 was not similarly affected, demonstrating distinct transcriptional regulation of the two ligands.\",\n      \"method\": \"Genetic knockout (NF-κB p50-/-p65+/- mice), dendritic cell expression assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with transcription factor validation, single lab, single method\",\n      \"pmids\": [\"14515254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PD-L2 inhibits human T cell proliferation, IL-2 and IFN-γ production via PD-1; this inhibition involves suppression of PI3K/AKT and ERK/MAPK pathways (PD-L2 inhibits anti-CD3-induced AKT phosphorylation within minutes and ERK phosphorylation after hours), and is accompanied by increased SHP-2 phosphatase activity associated with PD-1.\",\n      \"method\": \"Human T cell activation assays, phospho-AKT and phospho-ERK Western blotting, SHP-2 phosphatase activity assays, co-immunoprecipitation of SHP-2 with PD-1\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical assays (kinase/phosphatase activity, co-IP, Western blot), single lab\",\n      \"pmids\": [\"16278812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PDL2 negatively regulates T cell activation and tolerance via PD-1: antigen-presenting cells from PDL2-/- mice were more potent in activating T cells in a PD-1-dependent manner; PDL2-/- mice showed increased CD4+ and CD8+ T cell activation in vivo and abrogated oral tolerance.\",\n      \"method\": \"PDL2 knockout mouse generation, in vitro T cell activation assays with APCs, in vivo immunization and tolerance induction, PD-1-dependent rescue experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with both in vitro and in vivo phenotypic readouts, PD-1-dependence confirmed\",\n      \"pmids\": [\"16864790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PD-1/PD-L1, but not PD-1/PD-L2, interactions are crucial for attenuating T cell responses in experimental autoimmune encephalomyelitis (EAE): PD-L2-/- mice did not develop more severe EAE, unlike PD-1-/- and PD-L1-/- mice which showed elevated IFN-γ, TNF, IL-6, and IL-17.\",\n      \"method\": \"PD-L2-/- mouse immunization for EAE induction, cytokine measurement by ELISA, disease severity scoring\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined disease phenotype and cytokine readouts, single lab; notable as a negative finding distinguishing PD-L2 from PD-L1 in this context\",\n      \"pmids\": [\"17182110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PD-L2 on lung dendritic cells plays an inhibitory role on iNKT cell activation: PD-L2-/- mice showed greater airway hyperreactivity and higher IL-4 production by iNKT cells; blocking PD-L2 in vitro enhanced IL-4 production. PD-L2 expression on lung DCs is upregulated by allergen and IL-4. In contrast, PD-L1 deficiency reduced AHR, demonstrating opposing roles for the two ligands.\",\n      \"method\": \"PD-L2-/- and PD-L1-/- mouse models, allergen and α-GalCer challenge, iNKT cell transfer experiments, in vitro PD-L2 blockade, cytokine measurement\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal KO models (PD-L1-/- vs PD-L2-/-), cell transfer experiments, in vitro blockade, multiple orthogonal readouts\",\n      \"pmids\": [\"19741598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PD-L1 and PD-L2 bind PD-1 with comparable overall affinities but with distinct kinetic mechanisms: PD-L1 shows a delayed interaction consistent with conformational transition, while PD-L2 does not; PD-L1 and PD-L2 compete for the same PD-1 binding site.\",\n      \"method\": \"Surface plasmon resonance (SPR), cell surface binding assays, competition experiments with blocking mAbs\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — SPR-based real-time binding kinetics with multiple validation methods (cell binding, competition), single lab\",\n      \"pmids\": [\"20587542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PD-L2 is expressed on activated human CD4+ and CD8+ T cells (not only on APCs), and PD-L2 engagement at the surface of T cells downregulates cytokine production and cell proliferation, indicating a bidirectional regulatory role.\",\n      \"method\": \"Flow cytometry for PD-L2 surface expression on T cell subsets, functional assays with PD-L2 engagement on T cells\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct expression analysis and functional engagement on primary human T cells, single lab, two methods\",\n      \"pmids\": [\"21752471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PD-L2 promotes airway hyperresponsiveness via a PD-1-independent mechanism by inhibiting dendritic cell IL-12 production: PD-L2 blockade reduced allergen-induced AHR and enhanced serum IL-12, while PD-1 blockade had no effect; in vitro, PD-L2-Fc stimulation of DCs reduced IL-12 p70 production.\",\n      \"method\": \"PD-L2 blockade in murine asthma model, PD-1 blockade comparison, in vitro DC stimulation with PD-L2-Fc, IL-12 ELISA\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo blockade plus in vitro mechanistic assay, PD-1 independence confirmed by parallel blockade experiment, single lab\",\n      \"pmids\": [\"23149662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PD-L2 expression is primarily regulated by both IRF1 and STAT3 in response to interferons: IRF1 and STAT3 bind to the PD-L2 promoter; PD-L2 responds equally to interferon-beta and interferon-gamma, unlike PD-L1 which is primarily regulated by the IFN-γ-JAK1/JAK2-STAT1/STAT2/STAT3-IRF1 axis.\",\n      \"method\": \"siRNA knockdown of signaling components (JAK1, JAK2, STAT1, STAT2, STAT3, IRF1), chromatin immunoprecipitation (ChIP) for IRF1 and STAT3 at PD-L2 promoter, interferon stimulation of melanoma cells\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP demonstrating direct promoter binding combined with genetic knockdown, multiple transcription factors validated, replicated in patient biopsies\",\n      \"pmids\": [\"28494868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PD-L2 (B7-DC) binds RGMb (repulsive guidance molecule b) as a second receptor distinct from PD-1; a PD-1-binding-deficient PD-L2 mutant (K113S) retains binding to RGMb with similar affinity to wild-type and can costimulate CD4+ T cell Th1 responses via RGMb, promoting Th1 polarization and suppressing Th2-mediated asthma.\",\n      \"method\": \"PD-L2 K113S mutant protein binding assays, recombinant protein co-stimulation assays, RGMb expression analysis on immune cells, murine asthma model\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding assays with defined mutant plus functional T cell assays and in vivo disease model, single lab\",\n      \"pmids\": [\"28479601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PD-L2 has a higher affinity for PD-1 (approximately 3-fold) than PD-L1, attributable to two structural features that evolved in placental mammals: a C-D β-strand 'latch' that enhances affinity and a W110 'elbow' that acts to reduce engagement duration; these two opposing features combine to give the net 3-fold affinity advantage of PD-L2.\",\n      \"method\": \"Surface plasmon resonance (SPR) with recombinant proteins, mutational analysis of W110 and C-D region, phylogenetic analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — SPR-based real-time binding kinetics with systematic mutagenesis of key structural determinants, single lab with multiple orthogonal mutations tested\",\n      \"pmids\": [\"31882544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Binding of PD-L2 to human PD-1 induces formation of a prominent pocket in the CC' and FG loop regions of PD-1 via substantial conformational changes; a triple-mutant high-affinity PD-1 variant (two orders of magnitude higher affinity for PD-L2) enabled crystallization of the human PD-1/PD-L2 complex, revealing the structural basis of the interaction.\",\n      \"method\": \"Deep mutational scanning, yeast surface display selection, X-ray crystallography of human PD-1/PD-L2 complex at 2.0 Å and apo PD-1 at 1.2 Å\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structures combined with directed evolution and binding validation, multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"31727844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PD-L2 promotes osteosarcoma invasion and metastasis via tumor cell-intrinsic signaling through the RhoA-ROCK-LIMK2 pathway; PD-L2 knockdown suppresses migration and invasion, inhibits EMT, and reduces autophagy by decreasing beclin-1 expression; beclin-1 in turn regulates RhoA-ROCK-LIMK2 activity.\",\n      \"method\": \"PD-L2 siRNA knockdown in osteosarcoma cell lines, wound-healing and transwell assays, Western blotting for RhoA-ROCK-LIMK2, EMT markers and beclin-1, orthotopic nude mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro signaling pathway validation plus in vivo metastasis model, single lab\",\n      \"pmids\": [\"30886151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A super-enhancer (PD-L1L2-SE) located between the CD274 and CD273 genes drives synchronous co-expression of both PD-L1 and PD-L2 in cancer cells; genetic deletion of PD-L1L2-SE profoundly reduces expression of both ligands and abolishes immune evasion, rendering cells sensitive to T cell-mediated killing.\",\n      \"method\": \"Super-enhancer inhibitor treatment, CRISPR-based genetic deletion of PD-L1L2-SE, RNA-seq, ChIP-seq, T cell killing assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — genetic deletion of regulatory element with direct functional consequence validated by multiple orthogonal methods in one study\",\n      \"pmids\": [\"31825827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PD-L1L2 super-enhancer region (chr9:5,400,000-5,600,000) forms a topologically associating domain (TAD) around CD274 and CD273 that allows transcription factors STAT3 and IRF1 to be recruited to the PD-L1 locus to drive synchronous transcription of PD-L1 and PD-L2.\",\n      \"method\": \"Hi-C chromatin conformation analysis, ChIP-seq for STAT3 and IRF1, super-enhancer mapping\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromatin architecture analysis combined with transcription factor ChIP, single lab, review incorporating original data\",\n      \"pmids\": [\"35530130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PD-L2 expressed on tumor cells in the presence of PD-L1 suppresses tumor antigen-specific CD8+ T cell responses; PD-L2-only tumors confer resistance to anti-PD-L1 mAb that can be overcome by anti-PD-1 mAb or combined anti-PD-L2 mAb; PD-L2 is upregulated on tumor-associated macrophages when mice are treated with anti-PD-L1 mAb.\",\n      \"method\": \"Syngeneic mouse tumor models with PD-L1/PD-L2 combination knockouts, antibody treatments, flow cytometry for tumor-infiltrating lymphocytes and TAM phenotyping\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple tumor models with genetic manipulation of PD-L1/PD-L2, antibody blockade, and immune phenotyping; single lab\",\n      \"pmids\": [\"31076547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PD-L2 expression on tumor-associated macrophages (TAMs) becomes functionally relevant for immune suppression specifically when PD-L1 is blocked; anti-PD-L2 mAb treatment showed profound synergy with anti-PD-L1 mAb in anti-tumor responses, whereas anti-PD-L2 mAb alone had minimal effect; bone marrow chimera experiments showed that hematopoietic cell-derived PD-L1 (from BM-derived cells) also contributes to immune suppression.\",\n      \"method\": \"Anti-PD-L2/PD-L1 mAb treatment in tumor models, bone marrow chimeric mice, flow cytometry for TAM phenotyping\",\n      \"journal\": \"Cancer immunology, immunotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BM chimera experiments plus antibody combination studies, defined cellular localization of function, single lab\",\n      \"pmids\": [\"30357491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PD-L2 expression in non-small cell lung cancer is induced intrinsically by activating EGFR mutations and EML4-ALK fusion oncoproteins (suppressed by corresponding TKIs or siRNA knockdown), and extrinsically by IFN-γ via STAT1 signaling; STAT3 and c-FOS transcription factors contribute to both intrinsic and extrinsic pathways of PD-L2 induction.\",\n      \"method\": \"Stable expression of activated EGFR/EML4-ALK mutants in BEAS-2B cells, TKI treatment, siRNA knockdown of EGFR/ALK/STAT3/c-FOS, IFN-γ stimulation, RT-PCR and flow cytometry\",\n      \"journal\": \"Journal of thoracic oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function and loss-of-function experiments with multiple oncogene/transcription factor combinations, single lab\",\n      \"pmids\": [\"29596910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GATA2 is sufficient to drive constitutive PD-L2 (and PD-L1) expression in brain tumor cells and is necessary specifically for PD-L2 expression; GATA2 acts through cis-regulatory regions in the PDCD1LG2 locus; PD-L2 overexpression inhibits neoantigen-specific T cell IFN-γ production.\",\n      \"method\": \"Luciferase reporter assays with PDCD1LG2 cis-regulatory regions and GATA2 binding site mutations/deletions, flow cytometry for PD-L2 protein, IFN-γ ELISPOT for T cell function\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — luciferase reporter with regulatory element mutation plus functional T cell assay, single lab\",\n      \"pmids\": [\"32493985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PD-L2 undergoes N-glycosylation by FUT8 (fucosyltransferase), a transcriptional target of STAT3; glycosylated PD-L2 forms a complex with EGFR, activating EGFR/STAT3 signaling and reducing cetuximab binding affinity to EGFR; glycosylation stabilizes PD-L2 by blocking ubiquitin-dependent lysosomal degradation and promotes PD-L2 binding to PD-1 and immune evasion.\",\n      \"method\": \"Co-immunoprecipitation of PD-L2 with EGFR, N-glycosylation site mutagenesis, FUT8 knockdown, ubiquitination assays, STAT3 inhibitor treatment, in vitro T cell cytotoxicity, in vivo tumor model\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods (Co-IP, mutagenesis, ubiquitination, in vitro/in vivo functional assays) establishing post-translational modification mechanism, single lab\",\n      \"pmids\": [\"34697216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PD-L2 suppresses T cell signaling by forming coinhibitory microclusters ('PD-1 microclusters') with SHP2 phosphatase at the immunological synapse; PD-L2 competes with PD-L1 for the same PD-1 binding space at TCR microclusters; PD-1 microcluster formation (visible by imaging) is inhibited by specific mAbs.\",\n      \"method\": \"High-resolution live-cell imaging (super-resolution microscopy), PD-1/PD-L2 microcluster visualization, SHP2 co-localization analysis, competition experiments with PD-L1, mAb functional inhibition assays\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct high-resolution imaging of signaling complexes with functional mAb validation and competition assay, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"33990697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PD-L2 controls peripherally induced regulatory T (pTreg) cell numbers and function via PD-1/PD-L2 interactions: PD-L2 deficiency reduces splenic pTreg numbers, decreases IL-10 production, impairs suppressive activity, lowers Foxp3 expression, increases TSDR methylation, and disrupts mitochondrial TCA cycle/ATP production in pTregs; PD-L2high DC transfer restores pTreg numbers in PD-L2KO mice.\",\n      \"method\": \"PD-L2-/- mouse model, in vitro iTreg generation, TSDR methylation analysis, mitochondrial metabolic assays (TCA cycle, ATP), adoptive transfer of PD-L2high DCs, pyruvate rescue experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple orthogonal mechanistic readouts (epigenetic, metabolic, functional), DC transfer rescue, in vitro and in vivo validation\",\n      \"pmids\": [\"36045140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The gut microbiome downregulates PD-L2 expression and its binding partner RGMb to promote anti-tumor immunity; antibody-mediated blockade of the PD-L2-RGMb pathway (separate from PD-1) combined with anti-PD-1 or anti-PD-L1 promotes anti-tumor responses in multiple tumor models resistant to PD-1/PD-L1 blockade alone, including germ-free and antibiotic-treated mice.\",\n      \"method\": \"PD-L2 and RGMb antibody blockade in germ-free/antibiotic-treated/conventionally colonized mouse tumor models, conditional RGMb deletion in T cells, fecal transplant experiments, gene expression analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic conditional KO combined with antibody blockade across multiple independent tumor models and germ-free conditions, identifying mechanistic pathway\",\n      \"pmids\": [\"37138075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PD-L2 is upregulated upon induction of cellular senescence in cancer cells (identified by unbiased proteomics); PD-L2 is required for senescent cancer cells to evade immune clearance—PD-L2-deficient senescent cells are rapidly eliminated; PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo CD8 T cell-driven regression after chemotherapy.\",\n      \"method\": \"Proteomics screen, PD-L2 knockout in cancer cell lines, murine tumor models with chemotherapy, flow cytometry for immune cell infiltrates (MDSC, CD8 T cells), senescence assays\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined cellular phenotype and mechanism (MDSC recruitment, CD8 T cell response), multiple tumor models, unbiased discovery approach\",\n      \"pmids\": [\"38267628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PD-L2 regulates B-1 cell natural antibody production against phosphorylcholine (PC) via an IL-5-dependent mechanism: B-1 cell-intrinsic PD-L2 expression inhibits IL-5 production by T cells, which in turn limits B-1 cell plasmablast differentiation and PC-specific IgM production; PD-L2 mAb blockade increased IL-5+ T cells and CD138/Blimp1 expression on B-1 cells.\",\n      \"method\": \"PD-L2-/- mice and irradiated chimeras reconstituted with PD-L2-/- B cells, in vitro B-1 cell culture with PD-L2 mAb blockade, IL-5 neutralization and STAT5 inhibition, flow cytometry, ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific chimera experiments plus in vitro blockade with pathway rescue, single lab\",\n      \"pmids\": [\"28768724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PD-L2 induction on dendritic cells by Mycobacterium avium is mediated through the TLR2-p38 MAPK signaling pathway and requires IL-10 production; M. avium-exposed DCs with PD-L2 expression impair activation of BCG-specific T cells through PD-1:PD-L interactions.\",\n      \"method\": \"Bone marrow-derived DC stimulation with M. avium, TLR2 knockdown, p38 MAPK inhibition, IL-10 neutralization, flow cytometry for PD-L2, antigen-specific T cell activation assays\",\n      \"journal\": \"Tuberculosis (Edinburgh, Scotland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection with inhibitors and neutralization combined with functional T cell assays, single lab\",\n      \"pmids\": [\"21147037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PD-L2 is predominantly expressed on the surface of exosomes derived from clear cell renal cell carcinoma (ccRCC) cells; tumor-derived exosomal PD-L2 (TDE-PD-L2) suppresses T cell function in a PD-1-dependent manner, increasing regulatory T cells and decreasing cytotoxic CD8+ T cells both in tumor-infiltrating and splenic compartments; anti-PD-L2 antibody restores immune function.\",\n      \"method\": \"Exosome isolation and characterization, flow cytometry for surface PD-L2 on exosomes, in vitro T cell co-culture assays, in vivo tumor models with immune-competent vs immunodeficient mice, antibody blockade\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — exosome characterization with PD-1-dependent functional validation in vitro and in vivo, single lab\",\n      \"pmids\": [\"39511147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In gastric cancer, tumor cell-derived G-CSF induces FasL and PD-L2 expression on neutrophils via the JAK-STAT3 signaling pathway, while Th17 cell-derived IL-17A induces FasL and PD-L2 via ERK-NF-κB signaling; FasL+ PD-L2+ neutrophils acquire immunosuppressive functions that suppress tumor-specific CD8+ T cells in a manner reversible by blocking FasL and PD-L2.\",\n      \"method\": \"Cytokine stimulation of neutrophils, JAK/STAT3 and ERK/NF-κB inhibitor assays, flow cytometry for FasL and PD-L2, co-culture with CD8+ T cells, in vivo tumor growth assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway inhibitor experiments defining signaling cascade, in vitro and in vivo functional validation, single lab\",\n      \"pmids\": [\"34957697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Matrix stiffness-induced PD-L2 suppresses ferroptosis in hepatocellular carcinoma: SMYD3 (a histone methyltransferase) activated by matrix stiffening drives H3K4me3-mediated transcriptional induction of PD-L2, which then acts as an RNA-binding protein to enhance mRNA stability of FTL (ferritin light chain), elevating FTL protein and inhibiting xCT (SLC7A11)-mediated ferroptosis.\",\n      \"method\": \"SMYD3 knockdown/overexpression, H3K4me3 ChIP, PD-L2 knockdown on stiff substrates, ferroptosis assays (cell viability, ferrous iron, mitochondrial pathology), FTL mRNA stability assays, in vivo tumor model\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional ferroptosis assays and RNA stability experiments, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"39159723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SPHK1/S1P signaling promotes PD-L2 expression in bladder cancer via Akt/β-catenin activation; PD-L2 then interacts with c-Src (co-immunoprecipitation confirmed), which further activates FAK, promoting cancer cell invasion and migration.\",\n      \"method\": \"CRISPR/Cas9 SPHK1 KO and constitutive activation, PD-L2 knockdown/overexpression, co-immunoprecipitation of PD-L2 with c-Src, FAK phosphorylation assays, invasion/migration assays, in vivo tumor model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing PD-L2/c-Src interaction, genetic manipulation with functional readouts, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"39284838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EBV microRNA BHRF1-2-5p binds to the 3'UTR of PD-L2 (and PD-L1) mRNA to reduce their surface protein expression, acting as a counterregulatory mechanism to fine-tune LMP1-driven amplification of PD-L2 expression in EBV+ DLBCL.\",\n      \"method\": \"3'UTR reporter assays, EBV-infected B cell differentiation model, EBV miR BHRF1-2-5p overexpression/inhibition, flow cytometry for surface PD-L2\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional 3'UTR validation and miRNA manipulation with protein level readout, single lab\",\n      \"pmids\": [\"31856276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Topical siRNA silencing of PD-L2 in cutaneous dendritic cells inhibits elicitation of contact hypersensitivity by suppressing early pro-inflammatory cytokine expression and migration of hapten-carrying DCs to lymph nodes; this effect is independent of PD-1/PD-L1 but dependent on local memory T cells, suggesting PD-L2 acts as a costimulator in this context.\",\n      \"method\": \"Topical siRNA application, anti-PD-L2 mAb injection, CHS assay in PD-1/PD-L1 double KO mice, T cell transfer experiments, cytokine measurement\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown and antibody blockade with PD-1/PD-L1 KO controls, multiple functional readouts, single lab\",\n      \"pmids\": [\"30978356\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PD-L2 (PDCD1LG2) is a cell-surface ligand that binds PD-1 with ~3-fold higher affinity than PD-L1 (due to a C-D 'latch' and W110 'elbow' in its IgV domain) and suppresses T cell activation by forming PD-1 microclusters that recruit SHP-2 phosphatase to dephosphorylate TCR/CD3 signaling components, thereby inhibiting PI3K/AKT and ERK/MAPK pathways; its expression is transcriptionally co-regulated with PD-L1 by a shared super-enhancer (PD-L1L2-SE) and by STAT3/IRF1 downstream of IFN-β/γ, NF-κB, and oncogenic EGFR/ALK signaling, and post-translationally stabilized by FUT8-mediated N-glycosylation; beyond PD-1, PD-L2 also signals through RGMb to costimulate Th1 responses and, in a cell-intrinsic capacity, promotes tumor metastasis via RhoA-ROCK-LIMK2, suppresses ferroptosis via SMYD3/H3K4me3-FTL stabilization, and interacts with c-Src/FAK to drive invasion, while on immune cells it limits pTreg Foxp3 stability through metabolic (TCA cycle/ATP) regulation, regulates B-1 cell natural antibody production via IL-5 suppression, and is upregulated on therapy-induced senescent tumor cells to mediate MDSC recruitment and immune evasion.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PDCD1LG2 (PD-L2/B7-DC) is a cell-surface immunoglobulin-superfamily ligand that functions as a coinhibitory checkpoint on antigen-presenting cells, restraining T cell activation by engaging PD-1 [#0, #5]. Through its IgV domain it binds PD-1 with roughly 3-fold higher affinity than PD-L1, a property conferred by a C-D \\u03b2-strand 'latch' and a W110 'elbow' that respectively enhance affinity and limit engagement duration, and the two ligands compete for the same binding site on PD-1 [#8, #13, #14]. Engagement triggers PD-1 microcluster formation at the immunological synapse that recruits SHP-2 phosphatase, suppressing TCR-driven PI3K/AKT and ERK/MAPK signaling and arresting proliferation and cytokine production [#4, #23]. Its expression is differentially controlled relative to PD-L1: it is induced by IL-4/STAT6 during alternative macrophage activation, by NF-\\u03baB, and equally by IFN-\\u03b2 and IFN-\\u03b3 through direct promoter binding of IRF1 and STAT3 [#1, #3, #11]. In cancer, PD-L2 is co-regulated with PD-L1 by a shared super-enhancer organized within a TAD that recruits STAT3/IRF1 to drive synchronous transcription, is driven by oncogenic EGFR/ALK signaling, and is post-translationally stabilized by FUT8-mediated N-glycosylation that blocks lysosomal degradation and promotes EGFR complex formation [#16, #17, #20, #22]; loss of these ligands restores T cell-mediated tumor killing [#16, #26]. Beyond PD-1, PD-L2 binds a second receptor, RGMb, through which it costimulates Th1 responses, and blockade of the PD-L2-RGMb axis sensitizes PD-1/PD-L1-resistant tumors [#12, #25]. PD-L2 also exerts cell-intrinsic, receptor-independent functions in tumor cells, promoting invasion and metastasis via RhoA-ROCK-LIMK2 and c-Src/FAK signaling and suppressing ferroptosis by acting as an RNA-binding protein that stabilizes FTL mRNA [#15, #31, #32]. On immune cells it sustains peripherally induced Treg numbers and function through metabolic regulation and limits B-1 cell natural antibody production via IL-5 suppression [#24, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that PD-1 has a second ligand beyond PD-L1 and that this ligand delivers an inhibitory signal to T cells, defining PD-L2 as a coinhibitory checkpoint molecule.\",\n      \"evidence\": \"Cell-based binding and T cell proliferation/cytokine assays with Western blotting for SHP-2 phosphorylation\",\n      \"pmids\": [\"11224527\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve structural basis of PD-1 binding\", \"Downstream signaling beyond SHP-2 recruitment not mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined PD-L2 as differentially regulated from PD-L1, induced by Th2/IL-4-STAT6 and NF-\\u03baB rather than the classical activation pathway, indicating context-specific deployment of the two ligands.\",\n      \"evidence\": \"Macrophage and dendritic cell stimulation in STAT6-/-, STAT1-/-, and NF-\\u03baB p50-/-p65+/- knockouts with flow cytometry\",\n      \"pmids\": [\"12697896\", \"14515254\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter elements bound by these factors not mapped\", \"Human regulation not directly tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Provided early evidence for a PD-1-independent costimulatory function, hinting at a second receptor for PD-L2 long before its identification.\",\n      \"evidence\": \"Tumor rejection and cytotoxicity assays using PD-1-/- cells\",\n      \"pmids\": [\"12810690\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the second receptor unknown at the time\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Connected PD-L2/PD-1 engagement to specific intracellular cascades, showing rapid AKT and delayed ERK suppression downstream of SHP-2 activation in human T cells.\",\n      \"evidence\": \"Human T cell assays with phospho-AKT/ERK blotting, SHP-2 phosphatase activity, and PD-1 co-IP\",\n      \"pmids\": [\"16278812\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Spatial organization of signaling not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetic knockout established that PD-L2 negatively regulates T cell activation and oral tolerance in a PD-1-dependent manner in vivo.\",\n      \"evidence\": \"PDL2-/- mice with in vitro/in vivo T cell activation and tolerance assays plus PD-1-dependence tests\",\n      \"pmids\": [\"16864790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific contributions not dissected\", \"Did not address non-PD-1 receptor\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated that PD-L1 and PD-L2 can play opposing roles in tissue immunity, distinguishing PD-L2's function from PD-L1 in airway disease.\",\n      \"evidence\": \"Reciprocal PD-L1-/- and PD-L2-/- mouse asthma models with iNKT transfer and in vitro blockade\",\n      \"pmids\": [\"19741598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of opposing effects unresolved\", \"Receptor mediating effect not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Resolved the binding kinetics relationship between PD-L1 and PD-L2 for PD-1, showing comparable affinity but distinct mechanisms and shared binding site.\",\n      \"evidence\": \"SPR, cell-surface binding, and competition assays with blocking mAbs\",\n      \"pmids\": [\"20587542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural determinants of kinetic differences not identified\", \"Functional consequence of kinetic distinction untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified RGMb as the long-sought second receptor for PD-L2 and showed it mediates PD-1-independent Th1 costimulation, explaining earlier PD-1-independent observations.\",\n      \"evidence\": \"K113S PD-1-binding-deficient PD-L2 mutant in binding and costimulation assays plus a murine asthma model\",\n      \"pmids\": [\"28479601\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RGMb downstream signaling not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established the dominant interferon-responsive transcriptional control of PD-L2 by IRF1 and STAT3, distinguishing it from the STAT1-centric regulation of PD-L1.\",\n      \"evidence\": \"siRNA knockdown of JAK/STAT/IRF components and ChIP at the PD-L2 promoter in melanoma cells\",\n      \"pmids\": [\"28494868\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address chromatin architecture\", \"Cooperation with PD-L1 locus not yet shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined the structural basis of PD-L2's affinity advantage, attributing the net 3-fold higher PD-1 affinity to a C-D latch and W110 elbow, and crystallized the human PD-1/PD-L2 complex.\",\n      \"evidence\": \"SPR with systematic mutagenesis, phylogenetic analysis, deep mutational scanning, and X-ray crystallography of the PD-1/PD-L2 complex\",\n      \"pmids\": [\"31882544\", \"31727844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of the affinity advantage in vivo not quantified\", \"Required a high-affinity PD-1 mutant for crystallization\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed that PD-L1 and PD-L2 are coordinately driven by a shared super-enhancer organized into a TAD recruiting STAT3/IRF1, linking the transcriptional logic of both ligands.\",\n      \"evidence\": \"CRISPR deletion of PD-L1L2-SE, RNA-seq, ChIP-seq, Hi-C, and T cell killing assays\",\n      \"pmids\": [\"31825827\", \"35530130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals activating the super-enhancer not fully mapped\", \"Generalizability across tumor types not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed tumor-cell-intrinsic, receptor-independent functions of PD-L2, driving invasion and metastasis through RhoA-ROCK-LIMK2 and autophagy regulation.\",\n      \"evidence\": \"PD-L2 knockdown in osteosarcoma lines with migration/invasion assays, pathway blotting, and orthotopic mouse model\",\n      \"pmids\": [\"30886151\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How surface PD-L2 transduces an intracellular signal unclear\", \"Single lab and tumor type\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified oncogenic drivers (EGFR mutations, EML4-ALK) and the macrophage compartment as sources of PD-L2 that become functionally important when PD-L1 is blocked, rationalizing combination checkpoint blockade.\",\n      \"evidence\": \"Oncogene gain/loss-of-function in lung cells, TKI/siRNA, and antibody combination plus BM chimera tumor experiments\",\n      \"pmids\": [\"29596910\", \"30357491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of tumor vs myeloid PD-L2 not quantified across cancers\", \"Single lab per study\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the spatial signaling mechanism, showing PD-L2 nucleates PD-1/SHP2 coinhibitory microclusters that compete with PD-L1 at TCR microclusters.\",\n      \"evidence\": \"Super-resolution live-cell imaging of PD-1 microclusters with SHP2 co-localization, competition, and mAb inhibition\",\n      \"pmids\": [\"33990697\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative threshold for inhibition not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established post-translational control of PD-L2 by FUT8-mediated N-glycosylation that stabilizes the protein, links it to EGFR signaling, and promotes immune evasion.\",\n      \"evidence\": \"Co-IP, glycosylation-site mutagenesis, FUT8 knockdown, ubiquitination and cytotoxicity assays, and in vivo tumor model\",\n      \"pmids\": [\"34697216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Glycan structures not fully characterized\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed an immune-intrinsic role for PD-L2 in sustaining peripheral Treg numbers and function through epigenetic and metabolic regulation of Foxp3 stability.\",\n      \"evidence\": \"PD-L2-/- mice with iTreg generation, TSDR methylation, mitochondrial metabolic assays, and DC transfer/pyruvate rescue\",\n      \"pmids\": [\"36045140\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link between PD-1 signaling and Treg metabolism mechanistically incomplete\", \"Human relevance not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed the gut microbiome modulates the PD-L2-RGMb axis and that blocking it overcomes resistance to PD-1/PD-L1 therapy, establishing therapeutic relevance of the second-receptor pathway.\",\n      \"evidence\": \"Antibody blockade in germ-free/antibiotic/colonized tumor models, conditional T cell RGMb deletion, and fecal transplant\",\n      \"pmids\": [\"37138075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Microbial species and metabolites responsible not fully defined\", \"RGMb downstream signaling incomplete\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded PD-L2's intrinsic repertoire by showing it acts as an RNA-binding protein to stabilize FTL mRNA and suppress ferroptosis, and by linking it to senescence-associated immune evasion and exosomal/c-Src-FAK invasion programs.\",\n      \"evidence\": \"SMYD3/H3K4me3 ChIP and ferroptosis assays, FTL mRNA stability assays, proteomics-based senescence screen with KO tumor models, exosome characterization, and PD-L2/c-Src Co-IP\",\n      \"pmids\": [\"39159723\", \"38267628\", \"39511147\", \"39284838\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RNA-binding mechanism of a surface ligand structurally unexplained\", \"Findings are single-lab and tumor-type specific\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a cell-surface ligand executes its diverse cell-intrinsic functions (RNA binding, cytoskeletal/invasion signaling) and how these reconcile with its canonical surface coinhibitory role remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking surface ligand and intracellular functions\", \"Topology enabling intracellular RNA binding unexplained\", \"RGMb downstream signaling cascade undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 5, 12]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [8, 13, 14]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 9, 23]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 5, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 23, 32]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [11, 16, 17]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PDCD1\", \"RGMb\", \"SHP2\", \"EGFR\", \"FUT8\", \"c-Src\", \"FTL\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}